Day: May 15, 2024

CULVER CITY, Calif., May 15, 2024 (GLOBE NEWSWIRE) — Snail, Inc. (NASDAQ: SNAL) (“Snail” or “the Company”), a leading, global independent developer and publisher of interactive digital entertainment, today announced financial results for its first quarter ended March 31, 2024. Tony Tian, Co-Chief Executive Officer commented, “I’m absolutely thrilled and humbled to take the helm as Co-CEO of Snail. This Company has an exceptionally talented team, ground-breaking technologies, and iconic franchises, like ARK, that have fostered passionate gamer communities worldwide. As someone who has been an avid ARK player, I have a deep, personal appreciation for the creativity and innovation of our Snail team. I am excited for Snail’s bright future and the opportunity to work with this passionate, talented and dedicated team.” First Quarter...

HORSHAM, Penn., May 15, 2024 (GLOBE NEWSWIRE) — STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended March 31, 2024 and provides a corporate update. First Quarter 2024 Highlights Revenue in the first quarter of 2024 was $6.8 million (-11% YOY) vs. $7.6 million in the first quarter of 2023 Global net recurring revenue in the first quarter of 2024 was $4.7 million (-10% YOY) vs. $5.2 million in the first quarter of 2023, and was negatively impacted by deferred billings Gross domestic recurring billings were $4.6 million (-3% YOY) vs. $4.7 million in the first quarter of 2023; the 3% YOY decline in 1Q24 halted...

Dosing of all patients in clinical trial of BT-600 has been successfully completed, with results anticipated in late Q2 2024 Clinical data on device function of the NaviCap™ platform to be presented at DDW on May 19 Partnering process for the BioJet oral delivery platform is progressing well Management will host conference call and webcast today at 4:30 PM Eastern / 1:30 PM Pacific SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today provided a corporate update and reported financial results for the first quarter ended March 31, 2024. “We were gratified to see the excellent interim results from our clinical trial for BT-600, where we observed a pharmacokinetic profile consistent with drug delivery and absorption in the colon,”...

Commercial Launch of Next-Generation Lap-Band® 2.0 FLEX Continues Significant Reduction in Overall Operating Expenses of 51% in the First Quarter of 2024 Compared to the First Quarter of 2023 Implementation of 2024 Cost Reduction Plan Continues, Expected to Reduce Operating Expenses by 55.4% Compared to 2023 Conference Call to be Held at 4:30 pm ET Today IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) — ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the first quarter ended March 31, 2024 and provided a corporate strategic update. First Quarter 2024 and Subsequent Highlights March 2024: Significantly strengthened the company’s intellectual property portfolio related to an intragastric balloon system. Specifically, received...

         PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL INFORMATION AS OF DECEMBER 31, 2023 AND THE KEY EVENTS OF THE PERIOD Clinical development Continuation of the conditional marketing authorisation application procedures with the European Medicines Agency (EMA) and Health Canada for masitinib in the treatment of amyotrophic lateral sclerosis (ALS) First complete bone marrow response in an acute myeloid leukemia patient in its AB8939 Phase I/II clinical trial New clinical development program for masitinib in sickle cell disease, among the winning projects to be funded under the sixth call for “Hospital-University Research in Health” (Recherche Hospitalo-Universitaire en santé) projects, part of the Future Investments Program Strengthening of intellectual property protection for masitinib in ALS, mastocytosis and prostate...

  Nilfisk, a leading global provider of professional cleaning products and services, reported its Q1 2024 results today with solid organic growth and gross margin increase. Revenue was 259.0 mEUR, up 2.6 mEUR compared with Q1 2023. Organic growth for Q1 2024 was 3.7%. The EBITDA margin before special items (bsi) was 13.2%, leading to an EBITDA before special items of 34.2 mEUR. René Svendsen-Tune, CEO of Nilfisk comments on the Q1 results: “Nilfisk delivered a solid set of results in line with plan for Q1 2024. Stabilization in EMEA and a positive change in US momentum delivered volume growth for our Professional Business. We also saw our Service Business continue to grow, alongside a strong rebound from the Consumer Business. Also, we are delighted to announce that we have retained our Gold EcoVadis status”. Nilfisk delivered a significant...

Q1 2024 net product revenues increased 515% year-over-year to $105.7 thousand. Gross profit increased from ($55.9 thousand) to $51.0 thousand. WASHINGTON, May 15, 2024 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, reported today their financial results for the first fiscal quarter of the 2024 year, ended March 31, 2024. Financial Highlights for the Quarter Ended March 31, 2024: Net product revenues increased approximately 515% from $17.17 thousand for the first quarter of 2023 to approximately $105.7 thousand for first quarter of 2024; the Company credits growth from domestic commercial sales of ARAKODA®. The Company achieved a gross profit of approximately $51.0 thousand in the first quarter of...